Akero Therapeutics (AKRO)
(Real Time Quote from BATS)
$22.49 USD
+0.30 (1.35%)
Updated Jul 9, 2024 01:24 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
AKRO 22.49 +0.30(1.35%)
Will AKRO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AKRO
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
Other News for AKRO
Class Action Lawsuit against Akero Therapeutics, Inc. (NASDAQ:AKRO)
Akero Therapeutics Shares Cross Above 200 DMA
Optimistic Buy Rating for Akero Therapeutics Amidst Promising Efruxifermin (EFX) Developments
Wolfe Research starts Akero at outperform, cites MASH drug prospects
Wolfe starts Madrigal at outperform, cites Rezdiffra launch